Verrica Pharmaceuticals announced Phase 2 clinical data showing their drug VP-315 may trigger an abscopal effect, reducing untreated basal cell carcinoma (BCC) tumors beyond the injection site. This suggests VP-315 could activate the immune system broadly, potentially treating multiple BCC lesions and residual disease after surgery. The data showed an average 86% tumor size reduction and complete clearance in some untreated tumors, indicating a promising non-surgical option for BCC patients. Verrica will present these findings at the 2026 Society for Investigative Dermatology Annual Meeting, aiming to further validate VP-315's unique benefits.
Solaris Energy Infrastructure (SEI) maintains a Buy rating with a new price target of $97, driven by strong growth from its Power Solutions segment and a 2.2GW contracted capacity with major tech clients. Its upcoming inclusion in the S&P SmallCap 60...
XRP Ledger's AI agents have completed over 1 million transactions but with low financial volume, indicating the AI economy is still in early stages. Bitcoin mining veteran Chandler Guo predicts Bitcoin will hit $120,000 within a year and $500,000 in ...
Argan, Inc. reported a strong first quarter for fiscal year 2027 with a 50% increase in revenue, reaching a record $290.9 million. This growth was fueled by multiple project completions and a robust $2.8 billion backlog, supported by rising energy de...
The Global X Russell 2000 Covered Call ETF (RYLD) provides a high monthly yield of 11.9% and achieved a 20.5% total return over the past year. However, its strategy involving at-the-money options causes structural net asset value (NAV) erosion and ca...
A Cambridge study found Ethereum's annual energy consumption at 7.87 gigawatt-hours, making it the second-least energy-intensive proof-of-stake (PoS) blockchain when adjusted for market value. This marks a significant improvement from its previous pr...
